Clinical Trial Update: Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the trough and peak effect of once-daily telmisartan 80 mg with hydrochlorothiazide 12.5 mg (Micardis Plus) using ambulatory blood pres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• Telmisartan (Telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension | Phase 3 | Status: COMPLETED